A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Barbital. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be increased when combined with Barbital. |
| Buprenorphine | Barbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Hydrocodone | Barbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Magnesium sulfate | The therapeutic efficacy of Barbital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Barbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Barbital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Mirtazapine | Barbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Orphenadrine | Barbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Barbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Pramipexole | Barbital may increase the sedative activities of Pramipexole. |
| Ropinirole | Barbital may increase the sedative activities of Ropinirole. |
| Rotigotine | Barbital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Barbital. |
| Suvorexant | Barbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Thalidomide | Barbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Barbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Dabrafenib | The serum concentration of Barbital can be decreased when it is combined with Dabrafenib. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Barbital. |
| Luliconazole | The serum concentration of Barbital can be increased when it is combined with Luliconazole. |
| Mefloquine | The therapeutic efficacy of Barbital can be decreased when used in combination with Mefloquine. |
| Orlistat | Orlistat can cause a decrease in the absorption of Barbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetaminophen | The metabolism of Acetaminophen can be increased when combined with Barbital. |
| Propacetamol | The metabolism of Propacetamol can be increased when combined with Barbital. |
| Chloramphenicol | The metabolism of Barbital can be decreased when combined with Chloramphenicol. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Barbital. |
| Felbamate | The serum concentration of Barbital can be increased when it is combined with Felbamate. |
| Griseofulvin | The serum concentration of Griseofulvin can be decreased when it is combined with Barbital. |
| Lamotrigine | The serum concentration of Lamotrigine can be decreased when it is combined with Barbital. |
| Mianserin | The therapeutic efficacy of Barbital can be decreased when used in combination with Mianserin. |
| Primidone | The risk or severity of adverse effects can be increased when Primidone is combined with Barbital. |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital. |
| Pyridoxine | The metabolism of Barbital can be increased when combined with Pyridoxine. |
| Teniposide | The serum concentration of Teniposide can be decreased when it is combined with Barbital. |
| Ulipristal | The serum concentration of Ulipristal can be decreased when it is combined with Barbital. |
| Voriconazole | The serum concentration of Voriconazole can be decreased when it is combined with Barbital. |
| Topotecan | Barbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Barbital. |
| Sodium oxybate | Barbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Barbital. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Barbital. |
| Warfarin | The metabolism of Warfarin can be increased when combined with Barbital. |
| Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Barbital. |
| (R)-warfarin | The metabolism of (R)-warfarin can be increased when combined with Barbital. |
| R,S-Warfarin alcohol | The metabolism of R,S-Warfarin alcohol can be increased when combined with Barbital. |
| S,R-Warfarin alcohol | The metabolism of S,R-Warfarin alcohol can be increased when combined with Barbital. |
| (S)-Warfarin | The metabolism of (S)-Warfarin can be increased when combined with Barbital. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Barbital. |
| Aminophylline | The therapeutic efficacy of Barbital can be decreased when used in combination with Aminophylline. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Barbital is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Barbital is combined with Botulinum toxin type B. |
| Meperidine | Barbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine. |
| Somatostatin | The risk or severity of adverse effects can be increased when Somatostatin is combined with Barbital. |
| Ethanol | Barbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Barbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital. |
| Citalopram | The risk or severity of adverse effects can be increased when Barbital is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Barbital is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Barbital is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Barbital is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Barbital is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Barbital is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Barbital is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Barbital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Barbital is combined with Alaproclate. |
| Naltrexone | The risk or severity of adverse effects can be increased when Barbital is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Barbital is combined with Bezitramide. |
| Morphine | The risk or severity of adverse effects can be increased when Barbital is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Barbital is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Barbital is combined with Hydromorphone. |
| Oxycodone | The risk or severity of adverse effects can be increased when Barbital is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Barbital is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Barbital is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Barbital is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Barbital is combined with Sufentanil. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Barbital is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Barbital is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Barbital is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Barbital is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Barbital is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Barbital is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Barbital is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Barbital is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Barbital is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Barbital is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Barbital is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Barbital is combined with Dextromoramide. |